We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
Cap. Flow
-$3.24B
Cap. Flow %
-16.98%
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$492M
2
AVGO icon
Broadcom
AVGO
+$292M
3
KKR icon
KKR & Co
KKR
+$280M
4
ROIV icon
Roivant Sciences
ROIV
+$248M
5
MA icon
Mastercard
MA
+$138M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 46.53%
2 Communication Services 11.31%
3 Financials 11.23%
4 Technology 10.28%
5 Consumer Discretionary 4.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
126
Krystal Biotech
KRYS
$9.83B
$258K ﹤0.01%
1,000
-1,000
-50% -$266K
OMER icon
127
Omeros
OMER
$1.24B
$243K ﹤0.01%
23,000
– –
ALMS
128
Alumis Inc
ALMS
$3.23B
$242K ﹤0.01%
+11,000
New +$275K
APLS
129
DELISTED
Apellis Pharmaceuticals
APLS
$241K ﹤0.01%
+6,000
New +$129K
HQY icon
130
HealthEquity
HQY
$8.76B
$234K ﹤0.01%
2,800
-2,200
-44% -$181K
SNDX icon
131
Syndax Pharmaceuticals
SNDX
$1.77B
$234K ﹤0.01%
10,000
– –
FOLD
132
DELISTED
Amicus Therapeutics
FOLD
$231K ﹤0.01%
16,000
– –
QURE icon
133
uniQure
QURE
$3.37B
$229K ﹤0.01%
14,000
– –
BCRX icon
134
BioCryst Pharmaceuticals
BCRX
$2.49B
$228K ﹤0.01%
24,000
– –
VCYT icon
135
Veracyte
VCYT
$3.32B
$225K ﹤0.01%
7,000
– –
GRFS
136
Grifois
GRFS
$5.29B
$225K ﹤0.01%
28,000
– –
ABVX
137
Abivax
ABVX
$10.4B
$223K ﹤0.01%
2,000
-385,000
-99% -$45.6M
GEHC icon
138
GE HealthCare
GEHC
$33.3B
$214K ﹤0.01%
3,000
– –
RVMDW icon
139
Revolution Medicines Inc Warrant
RVMDW
$123M
$209K ﹤0.01%
120,085
– –
HIMS icon
140
Hims & Hers Health
HIMS
$6.57B
$208K ﹤0.01%
10,000
-3,376,986
-100% -$79.8M
BLTE
141
Belite Bio
BLTE
$6.53B
$207K ﹤0.01%
+1,300
New +$219K
MMSI icon
142
Merit Medical Systems
MMSI
$5.42B
$207K ﹤0.01%
3,000
– –
SUPN icon
143
Supernus Pharmaceuticals
SUPN
$2.81B
$207K ﹤0.01%
+4,000
New +$204K
HR icon
144
Healthcare Realty
HR
$6.6B
$204K ﹤0.01%
12,000
– –
URGN icon
145
UroGen Pharma
URGN
$2.35B
$198K ﹤0.01%
11,000
– –
VIR icon
146
Vir Biotechnology
VIR
$1.56B
$197K ﹤0.01%
+22,000
New +$175K
PGEN icon
147
Precigen
PGEN
$2.18B
$194K ﹤0.01%
50,000
– –
SDGR icon
148
Schrodinger
SDGR
$1.32B
$193K ﹤0.01%
17,000
-54,000
-76% -$746K
DYN icon
149
Dyne Therapeutics
DYN
$4.8B
$181K ﹤0.01%
10,000
– –
NVAX icon
150
Novavax
NVAX
$1.33B
$179K ﹤0.01%
22,000
-173,000
-89% -$1.57M
4 5
6
7 8

Similar funds

VARA
Value Aligned Research Advisors Princeton, New Jersey $20.7B AUM 292.88% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
NAM
Nissay Asset Management Tokyo, Japan $18.9B AUM 27.21% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Farallon Capital Management withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.